Therapix Biosciences Ltd. (OTCMKTS: TRPXY) is a clinical-stage biotechnology company focused on the development of cannabinoid-based pharmaceutical therapeutics. The company’s research platform seeks to harness the potential of synthetic and natural cannabinoids to address a range of central nervous system and inflammatory disorders. Therapix is headquartered in Tel Aviv, Israel, with commercial and development operations in the United States.
The company’s lead prescription pipeline includes THX-110, an oral formulation of dronabinol designed for the treatment of moderate-to-severe autism spectrum disorder, and THX-120, a proprietary combination candidate targeting symptoms of schizophrenia and related psychotic disorders. Both programs have advanced through preclinical evaluation into early-stage clinical trials. In addition to its prescription drug efforts, Therapix operates a consumer health division, CBN Genesis, which markets CBN-based sleep and wellness products in the U.S. over-the-counter marketplace.
Therapix pursues strategic collaborations and licensing agreements to bolster its research and commercialization capabilities. The company’s cross-border structure allows it to engage clinical research organizations, academic institutions and regulatory bodies in both Israel and the United States. Its development strategy emphasizes rigorous clinical validation alongside scalable manufacturing and supply chain partnerships.
Under the leadership of Chief Executive Officer Miri Halperin Wernli, Therapix maintains a management team with experience in pharmaceutical development, regulatory affairs and commercial operations. The company’s board and advisory panels include professionals with deep expertise in neuroscience, cannabinoid science and global product launches, reflecting its commitment to translating research into therapeutic advances.
AI Generated. May Contain Errors.
